HRCM
VERV

Hood River Capital Management’s Verve Therapeutics VERV Stock Holding History

Hood River Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-344,776
Closed -$4.97M – 146
2023
Q1 		$4.97M Buy
344,776
+9,361
+3% +$183K 0.16% 80
2022
Q4 		$6.49M Buy
335,415
+293,955
+709% +$7.79M 0.24% 80
2022
Q3 		$1.42M Buy
+41,460
New +$1.32M 0.05% 91

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Hood River Capital Management's VERV Position: Q2 2023 in Review

Hood River Capital Management sold out of Verve Therapeutics (VERV) in Q2 2023, closing a stake of 344,776 shares — an estimated $4.97M sold.

Hood River Capital Management first reported a position in VERV in Q3 2022 and held it in 3 quarters. The position peaked at $6.49M in Q4 2022. 121 funds tracked by Wall St. Rank hold VERV as of Q2 2023.

  • Hood River Capital Management reported no remaining Verve Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Hood River Capital Management sold 344,776 Verve Therapeutics shares in Q2 2023, an estimated $4.97M.
  • Hood River Capital Management first reported a position in Verve Therapeutics in Q3 2022 and held it in 3 quarters.
  • Hood River Capital Management's Verve Therapeutics position peaked at $6.49M in Q4 2022.
  • 121 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2023.

Based on Hood River Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.